Future experiments may consider using the conditional knockout or pharmacological blockade of the Psap–Gpr37l1 pathway to verify its functional necessity in OPC replenishment and blood–brain barrier repair, offering translational insights into demyelinating diseases. This evidence concerns the gene PSAP and demyelinating disease.